Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Young (6-month-old) and adult (12-month-old) 3xTg-AD (triple transgenic Alzheimer's disease) mice
- Dose used in the study
- Ultramicronised palmitoylethanolamide delivered subcutaneously for 3 months
- Duration
- 3 months
- What was measured
- Mitochondrial bioenergetics and ATP homeostasis in frontal cortex and hippocampus, brain metabolism by MRI/MRS, and glutamate release in ventral hippocampus by in vivo microdialysis
What the authors reported
Chronic treatment eased the decrease in complex-I respiration rate and complex V (FoF1-ATPase) activity and the drop in ATP content in cortical mitochondria, but did not improve impaired mitochondrial bioenergetics or depolarisation-induced glutamate release in the hippocampus. Progressive metabolic changes resembling human Alzheimer's disease were seen in cortex and hippocampus and were not affected by treatment.
Limits of this study
A mouse model of Alzheimer's disease; it cannot show effect in people. The authors declare no commercial or financial conflicts of interest.
Source
PubMed 35686025 · doi:10.3389/fnagi.2022.890855
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.